Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes
Authors
Keywords
-
Journal
Nature Communications
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-12-22
DOI
10.1038/ncomms6893
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
- (2014) T. Nakaoku et al. CLINICAL CANCER RESEARCH
- Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case
- (2014) Chien-Hung Gow et al. MEDICAL ONCOLOGY
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- CD74-NRG1 Fusions in Lung Adenocarcinoma
- (2014) L. Fernandez-Cuesta et al. Cancer Discovery
- State of art fusion-finder algorithms are suitable to detect transcription-induced chimeras in normal tissues?
- (2013) Matteo Carrara et al. BMC BIOINFORMATICS
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway
- (2013) Morvarid Mohseni et al. NATURE CELL BIOLOGY
- The mutational landscape of adenoid cystic carcinoma
- (2013) Allen S Ho et al. NATURE GENETICS
- Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non-Small Cell Lung Cancer
- (2013) G. V. Hegde et al. Science Translational Medicine
- A worldwide trend of increasing primary adenocarcinoma of the lung
- (2013) Haruhiko Nakamura et al. SURGERY TODAY
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- State-of-the-Art Fusion-Finder Algorithms Sensitivity and Specificity
- (2013) Matteo Carrara et al. Biomed Research International
- TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions
- (2013) Daehwan Kim et al. GENOME BIOLOGY
- HNF4α as a Marker for Invasive Mucinous Adenocarcinoma of the Lung
- (2012) Masato Sugano et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but noKITmutations
- (2012) Daniel Wetterskog et al. HISTOPATHOLOGY
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
- (2012) Cole Trapnell et al. Nature Protocols
- A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites
- (2011) Costantino Errani et al. GENES CHROMOSOMES & CANCER
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
- (2011) Y. S. Ju et al. GENOME RESEARCH
- Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers
- (2011) Daniel Wetterskog et al. JOURNAL OF PATHOLOGY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma
- (2011) M. R. Tanas et al. Science Translational Medicine
- EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
- (2010) Lynette M. Sholl et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version
- (2010) B. Zhao et al. GENES & DEVELOPMENT
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
- (2010) Ryoichi Onozato et al. Journal of Thoracic Oncology
- Comprehensive comparative analysis of strand-specific RNA sequencing methods
- (2010) Joshua Z Levin et al. NATURE METHODS
- RNA sequencing: advances, challenges and opportunities
- (2010) Fatih Ozsolak et al. NATURE REVIEWS GENETICS
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- (2009) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer
- (2009) Xiao-Song Wang et al. NATURE BIOTECHNOLOGY
- Neuregulins and Cancer
- (2008) J. C. Montero et al. CLINICAL CANCER RESEARCH
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- (2008) J. P. Koivunen et al. CLINICAL CANCER RESEARCH
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started